#JPM26: Day 1 at the JP Morgan Healthcare Conference / Endpoints
ENDPOINTS / endpoints - It’s day 1 at the JP Morgan Healthcare Conference, and the mood heading into the week is one of cautious optimism. Biotech fundraising was off to a hot start in 2026. There ...
#healthcare #pharmaceuticals #biotech #digitalhealth
Saturday, January 17, 2026, 8:21 am / permalink 18125 / 9 stories in 7 wks
No Link Between Acetaminophen in Pregnancy and Autism, a New Study Finds / NYT
Azeen Ghorayshi / nytimes - The review looked at more than three dozen studies and found no evidence that acetaminophen increased the risk of neurodevelopmental disorders in children.
#healthcare #pharmaceuticals #publichealth #autism #infanthealth
Friday, January 16, 2026, 6:23 pm / permalink 18099 / 3 stories in 7 wks
Life-extending prostate cancer drug to be offered to thousands in England / BBC
bbc - Abiraterone will be available in a matter of weeks and will be offered to 7,000 men a year.
#healthcare #pharmaceuticals #publichealth #governmentpolicy
Friday, January 16, 2026, 2:22 pm / permalink 18069 / 9 stories in 7 wks
FDA rejects cancer therapy for rare post-transplant disease / Beckers
Ella Jeffries / beckershospitalreview - Atara Biotherapeutics received a second complete response letter from the FDA for its biologics license application for Ebvallo (tabelecleucel). The letter, received Jan. 9, said the FDA no longer considers the single-arm ALLELE trial adequate to support …
#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #drugdevelopment #fda
Friday, January 16, 2026, 11:55 am / permalink 18057 / 2 stories in 7 wks
Compounding pharmacy sues Eli Lilly, Novo Nordisk over GLP-1 access / Beckers
Ella Jeffries / beckershospitalreview - Strive Compounding Pharmacy filed a federal antitrust lawsuit Jan. 14 against Eli Lilly and Novo Nordisk, alleging the two drugmakers used their market power to restrict access to compounded GLP-1 medications and suppress competition. The lawsuit, filed i…
#obesity #healthcare #pharmaceuticals #drugpricing #elililly #novonordisk #weightloss #publichealth #biotech
Thursday, January 15, 2026, 1:23 pm / permalink 17926 / 4 stories in 7 wks
NVIDIA and Eli Lilly Launch $1B AI Co-Innovation Lab to Reinvent Drug Discovery / OncoDaily
oncodaily - Dave Ricks, Chair, CEO at Eli Lilly and Company, shared Eli Lilly and Company‘s post on LinkedIn, adding: “Exciting news from the JPMorgan Healthcare Conference: Lilly and NVIDIA are joining […]
#healthcare #pharmaceuticals #elililly #publichealth #biotech #drugdevelopment
Thursday, January 15, 2026, 1:23 pm / permalink 17925 / 2 stories in 7 wks
FDA moves to remove suicide warnings from GLP-1 weight loss drugs / Medical Express
medicalxpress - Federal health regulators say popular weight loss drugs like Wegovy and Zepbound do not increase the risk of suicidal thoughts, and they have asked drugmakers to remove those warnings from medication labels.
#obesity #healthcare #pharmaceuticals #elililly #novonordisk #weightloss #publichealth #governmentpolicy #fda
Thursday, January 15, 2026, 1:23 pm / permalink 17924 / 8 stories in 7 wks
Merck Could Strike 30 Billion Deal for Revolution Medicines / OncoDaily
oncodaily - According to the Financial Times, Merck is in talks to acquire Revolution Medicines, a Redwood City, California-based cancer drug developer, in a deal that could value the company at roughly […]
#healthcare #pharmaceuticals #publichealth #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment
Monday, January 12, 2026, 1:21 am / permalink 17767 / 2 stories in 1 month
Aktis Has First Biotech IPO of 2026, Raising $318M to Expand the Reach of Radiopharmaceuticals / MedCity
Frank Vinluan / medcitynews - Aktis Oncology’s IPO will support a pipeline of “miniprotein” radioconjugates that could offer advantages over other targeted radiation cancer treatments. In addition to its internal pipeline, Aktis has a discovery partnership with Eli Lilly. The post Akt…
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment
Saturday, January 10, 2026, 10:21 am / permalink 17733 / 8 stories in 2 months
FDA rejects Corcept’s cortisol-targeting drug for Cushing’s syndrome / Endpoints
Ayisha Sharma / endpoints - Corcept Therapeutics failed to secure US approval for its drug candidate as a hormonal disorder treatment. The FDA rejected Corcept’s selective cortisol modulator relacorilant for Cushing’s syndrome, according to a company
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda
Monday, January 5, 2026, 1:21 am / permalink 17484 / 2 stories in 2 months
Intratumoral Bacterial Burden Drives Immunotherapy Resistance in Head and Neck Cancer / OncoDaily
oncodaily - Immune checkpoint blockade (ICB) benefits only a subset of patients with head and neck squamous cell carcinoma (HNSCC), and commonly used biomarkers (PD-L1, TMB) remain imperfect in this setting. This […]
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment
Saturday, January 3, 2026, 11:20 am / permalink 17458 / 7 stories in 2 months
Judge blocks 340B rebate pilot program / Beckers
Ella Jeffries / beckershospitalreview - A federal judge granted a temporary restraining order blocking the Department of Health and Human Services from launching its 340B Rebate Model Pilot Program, which was scheduled to begin Jan. 1, 2026. U.S. District Judge Lance Walker of the District of M…
#healthcare #pharmaceuticals #drugpricing #publichealth #governmentpolicy
Saturday, January 3, 2026, 7:22 am / permalink 17451 / 5 stories in 2 months
Advocates Applaud DEA’s Fourth Extension of Remote Prescribing Flexibilities / MedCity
Marissa Plescia / medcitynews - The DEA extended telemedicine prescribing flexibilities for controlled substances through the end of 2026, drawing praise from telehealth advocates who are urging a permanent solution.The post Advocates Applaud DEA’s Fourth Extension of Remote Prescribing…
#healthcare #pharmaceuticals #publichealth #governmentpolicy
Friday, January 2, 2026, 6:22 pm / permalink 17439 / 9 stories in 2 months
AstraZeneca bets up to $2B on Jacobio’s pan-KRAS inhibitor for cancer / Endpoints
Ayisha Sharma / endpoints - AstraZeneca is spending $100 million upfront to secure ex-China rights for an early-stage cancer drug developed by Jacobio Pharma. The UK drugmaker will be responsible for advancing and selling the oral pan-KRAS inhibitor, JAB-23E73, in ...
#pharmaceuticals #biotech #mergersandacquisitions #drugdevelopment
Saturday, December 27, 2025, 6:20 am / permalink 17306 / 7 stories in 2 months
Sanofi buys hepatitis B vaccine maker Dynavax for $2.2B; gets CRL for MS drug / Endpoints
Elizabeth Cairns / endpoints - Sanofi is set to supplement its vaccine offering with the acquisition of Dynavax Technologies for $2.2 billion in cash, the companies said Wednesday. Separately, Sanofi said the ...
#healthcare #pharmaceuticals #publichealth #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment #vaccinesafety
Saturday, December 27, 2025, 2:21 am / permalink 17302 / 3 stories in 2 months
Novo Nordisk’s Wegovy Pill Becomes First FDA-Approved Oral GLP-1 Drug for Weight Loss / MedCity
Frank Vinluan / medcitynews - Beyond weight reduction and long-term maintenance of weight loss, the FDA decision for oral Wegovy covers use of the once-daily pill for reducing the risk of major cardiovascular events. Novo Nordisk expects the Wegovy tablet will launch in early January.…
#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #drugdevelopment #fda
Tuesday, December 23, 2025, 3:22 pm / permalink 17254 / 36 stories in 2 months
FDA Approved Rucaparib for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer / OncoDaily
oncodaily - On December 17, 2025, the FDA issued a regular approval for rucaparib (Rubraca®), marking the formal conversion of its earlier accelerated authorization into full approval for BRCA-mutated metastatic castration-resistant prostate […]
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda
Saturday, December 20, 2025, 9:20 pm / permalink 17185 / 13 stories in 2 months
FDA Removes Key Limitation on the Use of Real-World Evidence in Regulatory Reviews / OncoDaily
oncodaily - On December 15, 2025, the U.S. Food and Drug Administration (FDA) announced a significant update to its regulatory approach regarding the use of real-world evidence (RWE) in drug and medical […]
#healthcare #pharmaceuticals #publichealth #governmentpolicy #drugdevelopment #fda
Saturday, December 20, 2025, 4:21 pm / permalink 17179 / 13 stories in 2 months
Optum Rx: 100% of network community pharmacies shift to cost-based model / Fierce
fiercehealthcare - Earlier this year, Optum Rx announced that it would shift to a cost-based model, which would boost reimbursements for brand-name drugs at community pharmacies.
#healthcare #pharmaceuticals #drugpricing #corporatetakeover
Friday, December 19, 2025, 5:22 am / permalink 17127 / 4 stories in 2 months
Carolyn Bertozzi Returns to Eli Lilly and Company Board of Directors 2025 / OncoDaily
oncodaily - Eli Lilly and Company has announced the election of Carolyn R. Bertozzi, Ph.D., as a returning member of its Board of Directors, effective December 8, 2025. In her renewed role, […]
#healthcare #pharmaceuticals #elililly #biotech #drugdevelopment
Monday, December 15, 2025, 4:22 am / permalink 16960 / 2 stories in 2 months